Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$13.52 +2.0%	$14.42	$9.57 ▼ $30.41	$1.86B	0.99	1.45 million shs	1.05 million shs
BEAM Beam Therapeutics	$19.80 +1.4%	$21.89	$13.53 ▼ $35.25	$1.99B	2.02	1.39 million shs	1.27 million shs
JANX Janux Therapeutics	$32.23 +3.8%	$29.97	$22.52 ▼ $71.71	$1.90B	3.27	850,966 shs	397,710 shs
RLAY Relay Therapeutics	$3.26 +1.9%	$3.00	$1.78 ▼ $10.72	$552.64M	1.7	1.98 million shs	1.68 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+17.88%	-4.12%	-34.57%	-40.10%
BEAM Beam Therapeutics	0.00%	+14.82%	-12.11%	-24.66%	-8.70%
JANX Janux Therapeutics	0.00%	+4.58%	+6.70%	-28.69%	-34.48%
RLAY Relay Therapeutics	0.00%	+18.96%	+17.65%	-32.20%	-49.76%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5756 of 5 stars	3.3	1.0	3.4	3.5	2.5	0.0
BEAM Beam Therapeutics	3.0167 of 5 stars	4.5	1.0	0.0	2.4	2.5	0.6
JANX Janux Therapeutics	2.9895 of 5 stars	3.5	2.0	0.0	2.9	5.0	0.0
RLAY Relay Therapeutics	2.0548 of 5 stars	3.4	1.0	0.0	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.60	Moderate Buy	$41.44	206.54% Upside
BEAM Beam Therapeutics	3.00	Buy	$49.45	149.77% Upside
JANX Janux Therapeutics	3.09	Buy	$95.25	195.53% Upside
RLAY Relay Therapeutics	2.82	Moderate Buy	$18.36	463.30% Upside

Current Analyst Ratings Breakdown

Latest RLAY, JANX, BEAM, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/28/2025	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$42.00 ➝ $42.00
3/12/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/10/2025	BEAM Beam Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$34.00
3/10/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/10/2025	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$57.00
3/10/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$40.00
3/7/2025	RLAY Relay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/3/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$24.00 ➝ $25.00
3/3/2025	JANX Janux Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00

(Data available from 4/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$2.50M	742.61	N/A	N/A	$1.54 per share	8.78
BEAM Beam Therapeutics	$63.52M	31.35	N/A	N/A	$12.04 per share	1.64
JANX Janux Therapeutics	$10.59M	179.92	N/A	N/A	$7.46 per share	4.32
RLAY Relay Therapeutics	$10.01M	55.23	N/A	N/A	$5.90 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$5.17	N/A	N/A	N/A	N/A	-236.60%	-64.09%	5/8/2025 (Estimated)
BEAM Beam Therapeutics	-$132.53M	-$4.58	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	5/6/2025 (Estimated)
JANX Janux Therapeutics	-$58.29M	-$1.28	N/A	N/A	N/A	-463.91%	-10.47%	-9.86%	5/6/2025 (Estimated)
RLAY Relay Therapeutics	-$341.97M	-$2.39	N/A	N/A	N/A	N/A	-45.75%	-40.75%	5/1/2025 (Estimated)

Latest RLAY, JANX, BEAM, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	N/A	N/A	N/A	$116.27 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	N/A	N/A	N/A	$14.69 million	N/A
5/6/2025	Q1 2025	JANX Janux Therapeutics	-$0.42	N/A	N/A	N/A	$0.59 million	N/A
5/1/2025	Q1 2025	RLAY Relay Therapeutics	-$0.51	N/A	N/A	N/A	$0.01 million	N/A
2/27/2025	Q4 2024	JANX Janux Therapeutics	-$0.49	-$0.36	+$0.13	-$0.36	N/A	N/A
2/26/2025	Q4 2024	RLAY Relay Therapeutics	-$0.57	-$0.45	+$0.12	-$0.45	$5.53 million	N/A
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million
2/10/2025	Q1 2025	ARWR Arrowhead Pharmaceuticals	-$0.42	-$1.39	-$0.97	-$1.39	$19.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	$0.90	4.55%	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
BEAM Beam Therapeutics	N/A	5.69	5.69
JANX Janux Therapeutics	N/A	38.80	38.80
RLAY Relay Therapeutics	N/A	18.42	18.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
BEAM Beam Therapeutics	99.68%
JANX Janux Therapeutics	75.39%
RLAY Relay Therapeutics	96.98%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
BEAM Beam Therapeutics	4.20%
JANX Janux Therapeutics	29.40%
RLAY Relay Therapeutics	4.32%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	137.32 million	120.68 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	79.33 million	Optionable
JANX Janux Therapeutics	30	59.11 million	37.05 million	Optionable
RLAY Relay Therapeutics	330	169.52 million	160.15 million	Optionable

RLAY, JANX, BEAM, and ARWR Headlines

Recent News About These Companies

Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025

April 28 at 4:16 PM | globenewswire.com

Relay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on Thursday

April 26 at 2:34 AM | marketbeat.com

Insider Selling: Relay Therapeutics, Inc. (NASDAQ:RLAY) CEO Sells 61,422 Shares of Stock

April 25 at 5:31 AM | insidertrades.com

Relay Therapeutics (RLAY) Expected to Announce Earnings on Thursday

April 24, 2025 | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives $18.36 Consensus Target Price from Brokerages

April 24, 2025 | americanbankingnews.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock Position Lifted by Geode Capital Management LLC

April 23, 2025 | marketbeat.com

Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Average Recommendation of "Moderate Buy" from Brokerages

April 22, 2025 | marketbeat.com

Renaissance Technologies LLC Grows Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)

April 21, 2025 | marketbeat.com

Franklin Resources Inc. Sells 1,338,037 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

April 21, 2025 | marketbeat.com

Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts

April 20, 2025 | insidermonkey.com

Wells Fargo & Company Begins Coverage on Relay Therapeutics (NASDAQ:RLAY)

April 20, 2025 | americanbankingnews.com

Relay Therapeutics (NASDAQ:RLAY) Coverage Initiated by Analysts at Wells Fargo & Company

April 19, 2025 | marketbeat.com

Walleye Capital LLC Has $3.82 Million Stake in Relay Therapeutics, Inc. (NASDAQ:RLAY)

April 19, 2025 | marketbeat.com

Wells Fargo Initiates Coverage of Relay Therapeutics (RLAY) with Equal-Weight Recommendation

April 18, 2025 | msn.com

Relay Therapeutics initiated with an Equal Weight at Wells Fargo

April 17, 2025 | markets.businessinsider.com

Why Relay Therapeutics, Inc.’s (RLAY) Stock Is Down 6.34%

April 17, 2025 | aaii.com

Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds?

April 16, 2025 | msn.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

April 16, 2025 | zacks.com

Vanguard Group Inc. Acquires 566,595 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)

April 14, 2025 | marketbeat.com

JPMorgan Chase & Co. Has $20.51 Million Stock Holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY)

April 13, 2025 | marketbeat.com

Relay Therapeutics: Trying To Find That Right Price

April 12, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLAY, JANX, BEAM, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$13.52 +0.27 (+2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$13.52 0.00 (0.00%)

As of 04:24 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Beam Therapeutics NASDAQ:BEAM

$19.80 +0.28 (+1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$19.65 -0.15 (-0.75%)

As of 07:56 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Janux Therapeutics NASDAQ:JANX

$32.23 +1.18 (+3.80%)

Closing price 04:00 PM Eastern

Extended Trading

$32.20 -0.03 (-0.09%)

As of 04:05 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Relay Therapeutics NASDAQ:RLAY

$3.26 +0.06 (+1.88%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 -0.04 (-1.35%)

As of 05:50 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time